Patent ID: 8025877

Claim:
A method of treating a disease or disorder correlated with an aberrant level of S1P, comprising administering to a subject known or suspected to be suffering from a disease or disorder correlated with an aberrant level of sphingosine-1-phosphate (S1P) a therapeutically effective amount of an isolated humanized antibody, or an antigen binding fragment thereof, that binds S1P to effect treatment of the disease or disorder, wherein the antibody or an antigen binding fragment thereof comprises at least one heavy chain variable domain and at least one light chain variable domain, wherein: A. each heavy chain variable domain comprises the following: (i) a first sequence of amino acid residues of sequence DHTIH (SEQ ID NO: 13); (ii) a second sequence of amino acid residues selected from the group consisting of AISPRHDITKYNEMFRG (SEQ ID NO: 31) and CISPRHDITKYNEMFRG (SEQ ID NO:14), provided that if the second sequence of amino acid residues is CISPRHDITKYNEMFRG (SEQ ID NO:14), the heavy chain variable domain is humanized; and (iii) a third sequence of amino acid residues of sequence GGFYGSTIWFDF (SEQ ID NO: 15); and B. each light chain variable domain comprises the following: (i) a first sequence of amino acid residues of sequence ITTTDIDDDMN (SEQ ID NO: 10); (ii) a second sequence of amino acid residues of sequence EGNILRP (SEQ ID NO: 11); and (iii) a third sequence of amino acid residues of sequence LQSDNLPFT (SEQ ID NO: 12).